Tuberculosis (TB), is an infectious bacterial disease caused by Mycobacterium tuberculosis. According to the World Health Organization’s (WHO) estimation, by 2023, 10.8 million people were infected with the tuberculosis. Although tuberculosis is preventable and curable, 1.23 million patients died from the tuberculosis as per Global tuberculosis report 2025. The TB incidence rate was 131 (new cases per 100,000 population per year) and the case fatality rate was 11.5%. A major public health crisis and threat is Multidrug-resistant TB (MDR-TB) and around 2 in 5 people with drug-resistant TB accessed treatment in 2024. [1] According to National Tuberculosis Elimination Programme (NTEP) 2023 guideline, a combination of four to five medicines is needed for tuberculosis (TB) treatment. The standard anti-TB short course chemotherapy regimen is given as a fixed dose combination which comprised of isoniazid, rifampicin, pyrazinamide, ethambutol and /or streptomycin for a period 6-9 months. For Multidrug resistant TB (MDR-TB) patient, the combination of bedaquiline, levofloxacin, clofazimine, cycloserine and linezolid are used in intensive phase for 6 months, and levofloxacin, clofazimine, cycloserine and linezolid are used for 12 months. Some common adverse drug reactions (ADRs) noted due to first line anti-TB drugs are peripheral neuropathy, hepatotoxicity, cutaneous reaction, gastrointestinal tract (GIT) related nausea, vomiting, anorexia and orange staining of body fluid. [2, 3]
In India, the prevalence of adverse drug reactions (ADRs) associated with first-line anti-tubercular drugs is estimated to vary from 2.3% to 17% in previous studies. [4, 5] The prevalence of adverse drug reactions (ADRs) associated with second-line anti-tubercular drugs is also ranged from 35% to 75% in drug-resistant tuberculosis (DR-TB) patients according to previous studies. [6, 7] World health organization (WHO) definition of Adverse drug reactions (ADR) usually referred to as noxious and unintended response to a drug occurring at doses normally used in humans for the prophylaxis, diagnosis and treatment of disease or for modification of physiological function.
ADR may contribute to treatment non-adherence by increasing patient suffering and resulting in higher expenses from more outpatient visits, testing, more serious hospital stays. When a patient experiences adverse drug reactions (ADRs) during therapy, the likelihood of cessation and loss to follow-up increases, which can result in poor and unfavourable treatment outcomes. [2, 8] ADRs may be caused by a number of factors, including the timing of the event, the pattern of illness, laboratory test results, the type, dosage, or timing of drug administration, patient age, nutritional status, the presence of preexisting diseases, or dysfunctions (such as abnormal liver function, kidney function, HIV coinfection, and alcoholism). As a result, ongoing ADR surveillance is crucial, especially in drug-resistant TB cases where prompt ADR care and early diagnosis may determine a favourable outcome. [4]
At present, recent studies regarding prevalence of adverse drug reactions due to first line and second line anti tuberculosis drugs associated with the ADR pattern, severity and preventability is not done in peripheral tertiary care hospital in western India. Hence, this study will be carried out with objectives of studying pattern of ADRs caused by antitubercular drugs and assess the severity and causality between the anti-tubercular medications and adverse drug reactions in TB patients at tertiary care hospital.
This was a prospective observational study conducted at a tertiary care hospital over a period of 6 months. The study was initiated after obtaining approval from the Institutional Ethics Committee (IEC).
Patients diagnosed with pulmonary tuberculosis and receiving anti-tuberculosis treatment (ATT) were included in the study.
A prospective observational study was carried out after getting approval from Institutional Ethics Committee. Investigator visited department of tuberculosis and chest. For data collection, a suspected adverse drug reaction reporting form was used available on website of Pharmacovigilance Programme of India (PvPI). The study included any ADR that the consultant physician designated based on clinical observations, lab results, and medical records.
For every suspected ADR, the following information was documented:
All identified ADRs were evaluated using internationally recognized scales:
Data collected in the case record forms were entered into Microsoft Excel 2019. Quantitative data (e.g., age, weight) were expressed as Mean ± Standard Deviation (SD). Qualitative data (e.g., gender, ADR types, causality) were expressed as frequencies and percentages.
We analysed 74 adverse drug reaction reporting form during six months study period from patients who attended outpatient department of TB for treatment of Tuberculosis. In 74 patients, total 108 ADR were analysed. The reports were verified, analysed, assessed and reported to PvPI. The details of the observations of our study are summarized here.
The mean age of patient was 34.03 ±14.43 years with median age 33 (range=61, from 01 to 75). The majority of the study population falls within the 20–39 age group, accounting for over half of the participants. The gender distribution shows a higher enrollment of male patients compared to female patients. Most patients were prescribed a first-line treatment regimen. Among the 74 enrolled patients, the occurrence of Adverse Drug Reactions was categorized by whether patients experienced a single reaction or multiple complications. (Table 1)
Table 1: Demographic & baseline characteristics of enrolled TB patients
|
Characteristic |
Category |
n |
% |
|
Total enrolled patients |
|
|
|
|
Age (years) |
01-19 |
13 |
17.60 |
|
|
20-39 |
39 |
52.70 |
|
|
40 to 59 |
18 |
24.32 |
|
|
60 to 79 |
4 |
5.40 |
|
|
Mean ± SD |
|
— |
|
Gender |
Male |
42 |
56.74 |
|
|
Female |
32 |
42.26 |
|
Treatment Regimen |
First-line (HRZE/HRZS) |
60 |
81.08 |
|
|
Second-line (Bdq-based) |
14 |
18.92 |
The majority of patients, totalling 51 individuals (68.90%), reported experiencing only one adverse drug reaction during the study period. A significant portion of the cohort, 23 patients (31.10%), experienced two or more adverse drug reactions concurrently or sequentially. (Table 2)
Table 2: Overall incidence of ADRs among enrolled patients
|
Parameter |
n |
% |
|
Total number of ADRs reported |
|
|
|
Patients with single ADR |
51 |
68.90 |
|
Patients with multiple ADRs (≥2) |
23 |
31.10 |
The most frequent course of action was the permanent withdrawal of the suspected drug, occurring in 32 cases (43.24%). In 29 cases (39.18%), the drug was continued while the patient received symptomatic treatment to manage the reaction. A dose reduction was implemented for 13 patients (17.57%) to mitigate the adverse effects. (Table 3)
Table 3: Action taken following detection of ADR
|
Action Taken |
n |
% |
|
Drug withdrawn permanently |
32 |
43.24 |
|
Drug dose reduced |
13 |
17.57 |
|
Symptomatic treatment given; drug continued |
29 |
39.18 |
|
Total |
74 |
100 |
The clinical status of the 74 enrolled patients at the time of reporting revealed varying degrees of recovery from the identified ADRs. 9 patients (12.17%) had fully recovered from their adverse reaction at the time of data collection. 9 patients (12.17%) were in the process of recovering when the report was filed. In 1 case (1.36%), the patient had not yet recovered from the reaction. The outcome remained unknown for the majority of the cohort, involving 54 patients (72.98%). (Table 4)
Table 4: Outcome of ADRs
|
Outcome |
n |
% |
|
Recovered completely |
09 |
12.17 |
|
Recovering (at time of reporting) |
09 |
12.17 |
|
Not recovered |
01 |
1.36 |
|
Unknown |
54 |
72.98 |
|
Total |
74 |
100 |
The analysis of 108 reported ADRs shows that ADRs affected various physiological systems with a wide range of frequency: The Gastrointestinal system was the most frequently involved, accounting for 37.04% of all reported reactions. The Hepatobiliary system followed as the second most common site, representing 16.67% of cases. Systems such as Skin & appendages (9.26%), Renal system (8.33%), and Musculoskeletal system (7.41%) showed moderate involvement. Both the Nervous system and Blood and lymphatic system each accounted for 6.48% of the total ADRs. The special senses (0.93%) and cardiovascular system (1.85%) were the least frequently affected categories in this dataset. (Table 5)
Table 5: System/Organ-wise distribution of ADRs
|
System / Organ Involved |
N |
% |
|
Gastrointestinal system |
40 |
37.04 |
|
Hepatobiliary system |
18 |
16.67 |
|
Nervous system |
07 |
6.48 |
|
Skin & appendages |
10 |
9.26 |
|
Musculoskeletal system |
08 |
7.41 |
|
Special senses (eyes, ears) |
01 |
0.93 |
|
Renal system |
09 |
8.33 |
|
Cardiovascular system |
02 |
1.85 |
|
Blood and lymphatic |
07 |
6.48 |
|
Others |
06 |
5.56 |
|
Total |
108 |
100 |
The assessment of 108 ADR cases reveals the following severity profile: The vast majority of reported reactions fell into the Mild category, accounting for 86% of all cases followed by 12% of the total reported reactions were moderate category. Only 2% of the ADRs were classified as Severe. (Figure 1)
Figure 1. Severity assessment of reported ADR according to modified Hartwig and Siegel scale
The evaluation of 108 ADR cases using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) criteria. (Table 6) It shows the following distribution: The vast majority of reported reactions were classified as possible, accounting for 92% of all cases. This indicates a reasonable time sequence between drug administration and the reaction, though the event could also be explained by the patient's underlying disease or other medications. A smaller portion of cases, 8% were identified as Probable/Likely. These cases followed a reasonable time sequence, improved upon withdrawing the drug, and were unlikely to be attributed to disease. No ADRs in this dataset met the criteria for the Certain, Unlikely, Conditional/Unclassified, or Unassessable categories. (Figure 2)
Figure 2. Causality assessment of reported ADR according to WHO-UMC Scale
Table 6: WHO-UMC Causality Categories
|
Causality Term |
Assessment criteria |
|
Certain |
|
|
Probable / Likely |
|
|
Possible |
|
|
Unlikely |
|
|
Conditional / Unclassified |
|
|
Unassessable |
|
Preventability assessment was based on Schumock and Thronton scale and showed that the majority of the ADRs (67.30%) were not preventable, 27.10% ADRs were probably preventable and only 5.60% of ADRs were definitely preventable. (Figure 3)
Figure 3. Preventability assessment of ADRs by Schumock and Thronton Scale.
The management of Tuberculosis (TB) remains a major public health challenge, largely complicated by the high incidence of Adverse Drug Reactions (ADRs) associated with anti-tubercular therapy (ATT). In our study, 108 ADRs across 74 patients were evaluated to understand their demographic distribution, systemic impacts, severity, and causality profiles.
Demographic and Baseline Comparison
Our findings revealed that the mean age of the patients experiencing ADRs was 34.03 ± 14.43 years, with more than half (52.70%) falling within the young adult age bracket of 20–39 years. This population is generally younger than those reported in several other Indian studies, where mean ages ranged from 36 ± 12 years to 45.48 ± 17.88 years in studies done by Tripathy et al and Ravichandran et al respectively. [11, 12] However, it closely aligns with a study done by Ahmed et al, which reported a mean age of 35.86 ± 12.62 years. [13] This mirrors the global epidemiological trend where TB predominantly affects the economically productive young population.
Regarding gender, our study showed male predominance (56.74%) as compared to female enrollment (42.26%). This is consistent with results from Ludhiana (54% male), Hubli (58.3% male), and Bengaluru studies (57.9% male). [3, 13, 14] Conversely, studies done Navelkar et al and Upadhyay et al reported a female preponderance (65.22% and 54%, respectively), suggesting that geographic and socioeconomic factors may influence the gender distribution of ADRs. [15, 16]
The vast majority of our patients (81.08%) were on a standard first-line regimen (HRZE/HRZS), while a smaller subset (18.92%) received bedaquiline-based second-line regimens. Notably, 31.10 % of our cohort suffered from multiple concurrent or sequential ADRs, emphasizing the high overlapping toxicity burden of multi-drug combinations.
Systemic Distribution of ADRs
Understanding which physiological systems are most vulnerable helps clinicians implement targeted screening. In our dataset, the Gastrointestinal (GI) system was the most frequently affected system, accounting for 37.04% of all reported reactions. Common symptoms like nausea, vomiting, abdominal pain, and gastritis are widely documented with rifampicin, ethambutol, and pyrazinamide. This pattern is strongly supported by the majority of the studies done by Sharma et al (42.06%), Ravichandran et al (39%), Divakar et al (63.8%), Navelkar et al (39.39%) and Upadhyay et al (47.62%). [3, 12, 14, 15, 16]
The Hepatobiliary system was the second most common site, representing 16.67% of the cases. Drug-Induced Liver Injury (DILI) is the most clinically dangerous complication of first-line ATT (primarily caused by isoniazid and pyrazinamide). The relatively high incidence in our study underscores the mandatory need for baseline and periodic liver function tests (LFTs). This aligns with studies where liver and biliary systems were either the most common in study done by Tripathy et al (30.1%) or a significant contributor reported by Upadhyay et al (16.52%). [11, 16]
Moderate involvement was noted in the skin and appendages (9.26%) and the renal system (8.33%). Cutaneous reactions (ranging from mild pruritus to severe rashes) are frequently associated with rifampicin and pyrazinamide, while renal impacts are critical to monitor if aminoglycosides or ethambutol are utilized. Neurological and hematological systems were less frequently involved (6.48% each), followed by the cardiovascular system and special senses. Interestingly, a study among the Saharia tribe in Madhya Pradesh reported Central Nervous System (CNS) related ADRs (75.6%) as the most common, followed by GI symptoms (74.4%), while study done by Jorge et al in Philippines reported cutaneous reaction (ranging from mild skin reactions to severe skin rash due to hypersensitivity) related ADRs (66.14%) as the most common followed by the hepatobiliary system related ADRs (21.70%) as second common involving system which indicate that specific populations in different geographical area may exhibit different toxicity profiles. [2, 20]
Severity, Causality and Preventability Assessments
A highly encouraging finding from our study was the overall severity profile of the reported reactions. Using the Modified Hartwig & Siegel Scale, the vast majority (86%) of the ADRs were classified as Mild (Level 1), meaning they required no alterations to the primary drug treatment. Moderate reactions (Level 3) made up 12% of the dataset, requiring specific symptomatic or antidote treatments. Only a small fraction of ADRs (2%) escalated to a Severe (Level 5) classification, presenting life-threatening risks. No deaths or intensive care unit admissions were recorded. This high prevalence of mild reactions is mirrored in studies from Divakar et al in Bengaluru (100% mild) and Navelkar et al in Goa (84.85% mild). However, some centers reported higher severity, such as study done by Sharma et al in Ludhiana, where 66% were categorized as moderate, and Ravichandran et al in Puducherry, which reported an 18.5% rate of severe ADRs. [15, 16, 3, 13]
When evaluating causality using the WHO-UMC criteria, 92% of the reactions were categorized as Possible. This signifies that while the clinical events occurred within a reasonable time sequence after initiating anti-tubercular drugs, the symptoms could technically also be explained by the patient's underlying tubercular disease or other co-suspect medications. The remaining 8% of cases were deemed Probable/Likely, given that they clearly improved upon drug withdrawal and could not be reasonably attributed to the other co-suspect drugs and underlying illness. This differs significantly from most other studies where "Probable" was the dominant category. Ludhiana: Majority classified as probable, Divakar et al (Bengaluru): 100% probable, Navelkar et al (Goa): 72.73% probable. Upadhyay et al (Gandhinagar): 54.54% probable, Reason for higher "Possible" classification in our study that most of the patients had taken anti-TB regimen and difficult to exclude the other co-suspect drug effects or presence of concomitant medications in specific patient cohort. [3, 15, 16, 17]
Preventability assessment of ADRs were done by using Schumock and Throton scale and ADRs were classified as Not Preventable (67.30%), Probably Preventable (27.10%) and Definitely Preventable (5.60%) which is moreover similar with study done by Babu et al who reported 66.82% were non-preventable, 32.2% were probably preventable and 0.96% were definitely preventable. [19]
Clinical Management and Outcomes
The clinical response to detecting an ADR varied based on systemic severity. In 43.24% of cases, the suspected drug had to be permanently withdrawn. This rate of withdrawal is substantially higher than other reported figures, such as 12.5% of cases and 15.15% of cases reported by Ahmed et al and Navelkar et al respectively. [14, 16] Although the causative drug is successfully eliminated, this presents a strategic dilemma for the physicians, who must prescribed other, equally effective regimens without sacrificing the cure rate. In contrast, 39.18% of the cases allowed for the continuation of the drug paired with supportive symptomatic treatment (e.g., antiemetics for GI distress, antihistamines for mild pruritus). In 17.57% of cases, physicians reduced the dose of antitubercular drugs in response to ADRs.
Regarding patient outcomes, 12.17% of patients recovered from ADRs completely, and an equal number of patients 12.17% were actively recovering at the time the reports were finalized. Only 1.36% (a single patient) had not yet recovered. Despite these interventions, the outcome was unknown for 72.98% of total cases, highlighting a critical gap in long-term post-ADR follow-up. This is a common challenge in tertiary care settings, where patients may default once symptoms subside.
This study elucidates that adverse drug reactions (ADRs) constitute a substantial complication of anti-tuberculosis therapy (ATT), with a notable preponderance among young adult males (ages 20–39) receiving standard anti-tubercular regimens. Systemic analysis identifies the gastrointestinal and hepatobiliary systems as the primary sites of toxicity, necessitating the implementation of mandatory baseline and longitudinal liver function monitoring. While ADRs are frequent, the clinical severity profile remains largely favorable; with the vast majority of cases classified as mild and only 2% escalating to severe. Causality assessment using WHO-UMC criteria categorized most reactions as possible, primarily because concurrent multi-drug treatments made it difficult to isolate the effects of a single co-suspect medication.
The authors sincerely thank the Institutional Ethics Committee and the administration of GMERS Medical College and Hospital, Himmatnagar, for their approval and support. We are grateful to the clinicians, OPD staff of tuberculosis department for their cooperation, and to all patients who participated in the study. We also acknowledge the guidance and support of the faculty and colleagues from the Department of Pharmacology.
AUTHORS’ CONTRIBUTIONS
All authors contributed significantly to the conception and design of the study. Data collection was carried out collaboratively by the authors. Data analysis and interpretation were performed jointly. The manuscript was drafted and critically revised by all authors, and all authors read and approved the final version of the manuscript.
The author received no financial support for the research, authorship and/or publication of this article.
[1] World Health Organization. Global tuberculosis report 2025. WHO, Geneva, 2025 (WHO/CDS/TB/2025). Available at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2025).
[2] Mishra P, Bhat J, Yadav R, Sharma RK, Rao VG. Adverse drug reaction patterns of first?line anti?tubercular drugs among Saharia tuberculosis patients: An observational study in particularly vulnerable tribal group of Madhya Pradesh, India. Indian J Public Health 2023;67:542-5.
[3] Sharma C, Badyal DK, Mittal N, Gulrez G. Adverse Drug Reaction Pattern of First-Line Anti-tubercular Drugs in a Tertiary Care Hospital of Northern India. Int J Pharm Clin Res. 2023;15(2):63-71.
[4] Prasad R, Singh A, Gupta N. Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis. Ann Natl Acad Med Sci (India). 2021;57:16–35.
[5] Imam F, Sharma M, Khayyam KU, Al-Harbi NO, Rashid MK, Ali MD, Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs. Saudi Pharm J. 2020 Mar;28(3):316-324.
[6] Vaman RS, Thomas GD,Kalyanasundaram M, Soman S, Valamparampil MJ,Murhekar MV, Adverse Drug Reactions among persons initiated on treatment for Drug-Resistant Tuberculosis in Kerala, India: A non-concurrent cohort study, IJID Regions (2025).
[7] Massud A, Syed Sulaiman SA, Ahmad N, Shafqat M, Chiau Ming L, Khan AH. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study. Front Pharmacol. 2022 Jun 2;13:883483.
[8] WHO. International drug monitoring- the role of the national centres. Tech Rep ser WHO. No.; 1972:498.
[9] The use of the WHO-UMC system for standardized case causality assessment. [ May; 2024]. 2024.
[10] Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49(9):2229-32.
[11] Focusing on the preventability of adverse drug reactions. Schumock GT, Thornton JP. https://pubmed.ncbi.nlm.nih.gov/10118597/ Hosp Pharm. 1992;27:538.
[12] Tripathy R, Singh P, Behera D, Paikray E, Subhankar S, Das MC. Adverse drug reaction to first line oral antitubercular drugs: An 8 year analysis from a tertiary centre in Eastern India. Niger Postgrad Med J. 2026;33:25 8.
[13] Ravichandran M, Rajaram M, Munusamy M. Pharmacovigilance of Antitubercular Therapy in Tuberculosis. Cureus. 2022;14(2):e21915.
[14] Ahmed A, Gudagunti AK, Shylendra, Nayak VH, Swamy HM. Frequency and type of adverse drug reactions related to multidrug-resistant tuberculosis therapy. Int J Adv Med. 2021;8(8):1086-1091.
[15] Divakar M, Ananth R, Lalitha K. Incidence of Adverse Drug Reactions (ADRs) and their Determinants among Sputum-Positive Pulmonary TB Patients in A Metropolitan Area, Bengaluru: A Prospective Study. Natl J Community Med. 2023;14(10):628-634.
[16] Navelkar R, Pereira IA, Vaz FS. Adverse drug reactions to first line antituberculosis drugs at four DOTS centers in Goa, India. Indian J Health Sci Biomed Res. 2023;16:115-8.
[17] Upadhyay G, Shukla AB, Dave DJ. Causality assessment, severity and preventability of adverse drug reactions due to first-line antitubercular agents. Pharmaciana. 2022;12 (2):235-244.
[18] Kalaiselvan V, Shukla S, Kumar SR, Mishra N, Kumar P, Raghuvanshi RS. Adverse Drug Reactions Associated with Anti-Tuberculosis Therapy. In: New Insights into the Future of Pharmacoepidemiology and Drug Safety. IntechOpen; 2022.
[19] Babu L, et al. Adverse drug reactions among drug-resistant tuberculosis treatment: an observational cohort study. Int J Pharm Pharm Sci. 2021 Sep;13(9):50-55.
[20] Jorge MJ, Esporlas CB, Largoza MLE, Zamora R. Adverse Drug Events from First-line Anti-tuberculosis Drugs in a Tertiary Medical Center. EMJ. 2024;9(4):113-119.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications